Cidara Therapeutics Inc Stock
Your prediction
Cidara Therapeutics Inc Stock
Our community identified positive and negative aspects for Cidara Therapeutics Inc stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Cidara Therapeutics Inc stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 1.180% | 8.974% | 17.241% | -40.351% | -8.602% | -10.053% | -81.048% |
| Vaxart Inc. | 21.640% | -0.639% | -15.408% | -49.275% | -58.457% | -74.601% | -95.556% |
| Achieve Life Sciences Inc. | 1.550% | -1.382% | 1.552% | 1.290% | 10.098% | 62.459% | -37.200% |
Comments
News
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
California-based TCG Crossover Management fully exited its position in Cidara Therapeutics (NASDAQ:CDTX) during the third quarter, reducing its holdings by 1 million shares in a move valued at